Dose finding study of OMT-28 in subjects with persistent atrial fibrillation

Registry ID

EUCTR2018-001626-26

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

OMEICOS Therapeutics GmbH

Start date

2019-01-03

Completion date

2020-04-08

Last update

2026-08-16

Conditions

• Persistent atrial fibrillation

Summary

• To assess the efficacy of three different doses of OMT-28 administered once daily versus placebo in the maintenance of normal sinus rhythm after electrical direct current cardioversion (DCC) in patients with persistent AF treated with an appropriate anticoagulant therapy.

Locations

• , , Czechia
• , , Bulgarian Drug Agency
• , , Hungary

Related clinical trials

• ATrial Fibrillation Registry and BIobank UlM
• Psychobiological Predictors of Treatment Satisfaction and Outcomes Following Cardiac Interventions (PVI)
• Transcutaneous Vagal Nerve Stimulation for the Treatment of Persistent Atrial Fibrillation (VAST-AF): a Randomized, Controlled, Blinded, Monocentric, Clinical Trial
• Feasibility study: Evaluation of methods for continuous pain assessment based on contactless recording of vital and activity parameters
• Randomised comparison of two ablation index-based protocols for pulmonary vein isolation
• Mediastinal and esophageal alterations after pulmonary vein isolation

View on source registry